About: COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
Creator	Basse, Clémence Bellesoeur, Audrey Bidard, François-Clément Bozec, Laurence Cabel, Luc Cottu, Paul Diakite, Sarah Frelaut, Maxime Hequet, Delphine Kirova, Youlia Laas, Enora Noret, Aurélien Paoletti, Xavier Pierga, Jean-Yves Ramtohul, Toulsie Servois, Vincent Vuagnat, Perrine Curie, Institut Group, Covid
source	Medline; PMC
abstract	BACKGROUND: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). METHODS: An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities. RESULTS: Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N = 41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (> 70) were the two factors associated with a higher risk of intensive care unit admission and/or death. CONCLUSIONS: This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1186/s13058-020-01293-8
bibo:pmid	32460829
has license	cc-by
sha1sum (hex)	6fe9425f7c70628b6881f297cc8d2c84772bb906
schema:url	https://doi.org/10.1186/s13058-020-01293-8
resource representing a document's title	COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
has PubMed Central identifier	PMC7254663
has PubMed identifier	32460829
schema:publication	Breast Cancer Res
resource representing a document's body	covid:6fe9425f7c70628b6881f297cc8d2c84772bb906#body_text
is schema:about of	named entity 'REPORTED' named entity 'DEATHS' named entity 'FRANCE' named entity 'CURIE' named entity 'higher risk' named entity 'COVID-19' named entity 'mortality rate' named entity 'tumor' named entity 'ICU' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID' named entity 'ICU' named entity 'breast cancer' named entity 'ground-glass opacity' named entity 'immunomodulating' named entity 'China' named entity 'lymphopenia' named entity 'radiation therapy' named entity 'angiotensin-converting enzyme' named entity 'dyspnea' named entity 'March 2020' named entity 'chemotherapy' named entity 'COVID' named entity 'NSAID' named entity 'COVID-19' named entity 'COVID' named entity 'chest pain' named entity 'corticosteroids' named entity 'sequelae' named entity 'CDK4' named entity 'SARS-CoV-2' named entity 'autoimmune hepatitis' named entity 'follow-up' named entity 'France' named entity 'Nasopharyngeal swabs' named entity 'diabetes' named entity 'New Yorkers' named entity 'breast cancer' named entity 'metastatic breast cancer' named entity 'cardiovascular' named entity 'CT scan' named entity 'Radiology' named entity 'Germany' named entity 'ground-glass opacities' named entity 'RNA' named entity 'COVID' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'antibody' named entity 'treated symptomatically' named entity 'viral pandemic' named entity 'metastases' named entity 'retrospective study' named entity 'COVID' named entity 'hypertension' named entity 'ICU' named entity 'corticosteroids' named entity 'follow-up' named entity 'flowchart' named entity 'infection' named entity 'breast cancer' named entity 'Thrombotic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software